Statin use and asthma control in patients with severe asthma

Amir Zeki, Justin Oldham, Machelle Wilson, Olga Fortenko, Vishal Goyal, Michael Last, Andrew Last, Ayan Patel, Jerold A Last, Nicholas Kenyon

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objectives: We hypothesised that severe asthmatics taking a statin drug, in addition to inhaled corticosteroids/long-acting β-agonist inhaler therapy, would have better asthma symptom control and improved lung function compared to their controls. Study design: A retrospective, cross-sectional study of 165 patients with severe asthma seen from 2001-2008. Hierarchical linear and logistic regression models were used for modelling fitting. Setting: University of California, Davis Medical Center (Sacramento, California, USA). Academic, single-centre, severe asthma subspecialty clinic. Participants: 612 screened, 223 eligible and 165 adult patients were included in the final study (N=165; 31 statin users and 134 non-users). Primary and secondary outcome measures: The primary endpoint was asthma control as measured by the Asthma Control Test (ACT). The secondary endpoints included lung function, symptoms and the need for corticosteroid burst and peripheral eosinophil count. Results: At baseline, statin users compared to nonusers were older, had lower lung function (FEV 1% predicted, FEV1, forced vital capacity and FEF 25-75%) and had a higher prevalence of comorbid conditions. Statin use was associated with more aspirin and ipratropium inhaler use than in non-users. Patients in both groups were obese (body mass index ≥ 30). Statin users had better asthma symptom control compared to non-users (higher adjusted mean ACT score by 2.2±0.94 points, p<0.02). Median statin use was for 1 year. There were no statistically significant differences in lung function, corticosteroid or rescue bronchodilator use or peripheral eosinophilia between the two groups. Conclusions: In our severe asthma referral population, statin users already taking inhaled controller therapy achieved better asthma control compared to non-users. The implications of this study is that patients with severe asthma could potentially benefit from added statin treatment. Because our study population was on average obese, the obese severe asthmatic may be a viable asthma subphenotype for further studies. Prospective randomised clinical trials evaluating the safety and efficacy of statins in severe asthma are warranted.

Original languageEnglish (US)
Article numbere003314
JournalBMJ Open
Volume3
Issue number8
DOIs
StatePublished - 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Asthma
Lung
Adrenal Cortex Hormones
Nebulizers and Vaporizers
Logistic Models
Ipratropium
Bronchodilator Agents
Vital Capacity
Eosinophilia
Eosinophils
Population
Aspirin
Linear Models
Body Mass Index
Therapeutics
Referral and Consultation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Statin use and asthma control in patients with severe asthma. / Zeki, Amir; Oldham, Justin; Wilson, Machelle; Fortenko, Olga; Goyal, Vishal; Last, Michael; Last, Andrew; Patel, Ayan; Last, Jerold A; Kenyon, Nicholas.

In: BMJ Open, Vol. 3, No. 8, e003314, 2013.

Research output: Contribution to journalArticle

Zeki, Amir ; Oldham, Justin ; Wilson, Machelle ; Fortenko, Olga ; Goyal, Vishal ; Last, Michael ; Last, Andrew ; Patel, Ayan ; Last, Jerold A ; Kenyon, Nicholas. / Statin use and asthma control in patients with severe asthma. In: BMJ Open. 2013 ; Vol. 3, No. 8.
@article{696c18fd228a42ac9cab95abbbad7e4f,
title = "Statin use and asthma control in patients with severe asthma",
abstract = "Objectives: We hypothesised that severe asthmatics taking a statin drug, in addition to inhaled corticosteroids/long-acting β-agonist inhaler therapy, would have better asthma symptom control and improved lung function compared to their controls. Study design: A retrospective, cross-sectional study of 165 patients with severe asthma seen from 2001-2008. Hierarchical linear and logistic regression models were used for modelling fitting. Setting: University of California, Davis Medical Center (Sacramento, California, USA). Academic, single-centre, severe asthma subspecialty clinic. Participants: 612 screened, 223 eligible and 165 adult patients were included in the final study (N=165; 31 statin users and 134 non-users). Primary and secondary outcome measures: The primary endpoint was asthma control as measured by the Asthma Control Test (ACT). The secondary endpoints included lung function, symptoms and the need for corticosteroid burst and peripheral eosinophil count. Results: At baseline, statin users compared to nonusers were older, had lower lung function (FEV 1{\%} predicted, FEV1, forced vital capacity and FEF 25-75{\%}) and had a higher prevalence of comorbid conditions. Statin use was associated with more aspirin and ipratropium inhaler use than in non-users. Patients in both groups were obese (body mass index ≥ 30). Statin users had better asthma symptom control compared to non-users (higher adjusted mean ACT score by 2.2±0.94 points, p<0.02). Median statin use was for 1 year. There were no statistically significant differences in lung function, corticosteroid or rescue bronchodilator use or peripheral eosinophilia between the two groups. Conclusions: In our severe asthma referral population, statin users already taking inhaled controller therapy achieved better asthma control compared to non-users. The implications of this study is that patients with severe asthma could potentially benefit from added statin treatment. Because our study population was on average obese, the obese severe asthmatic may be a viable asthma subphenotype for further studies. Prospective randomised clinical trials evaluating the safety and efficacy of statins in severe asthma are warranted.",
author = "Amir Zeki and Justin Oldham and Machelle Wilson and Olga Fortenko and Vishal Goyal and Michael Last and Andrew Last and Ayan Patel and Last, {Jerold A} and Nicholas Kenyon",
year = "2013",
doi = "10.1136/bmjopen-2013-003314",
language = "English (US)",
volume = "3",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Statin use and asthma control in patients with severe asthma

AU - Zeki, Amir

AU - Oldham, Justin

AU - Wilson, Machelle

AU - Fortenko, Olga

AU - Goyal, Vishal

AU - Last, Michael

AU - Last, Andrew

AU - Patel, Ayan

AU - Last, Jerold A

AU - Kenyon, Nicholas

PY - 2013

Y1 - 2013

N2 - Objectives: We hypothesised that severe asthmatics taking a statin drug, in addition to inhaled corticosteroids/long-acting β-agonist inhaler therapy, would have better asthma symptom control and improved lung function compared to their controls. Study design: A retrospective, cross-sectional study of 165 patients with severe asthma seen from 2001-2008. Hierarchical linear and logistic regression models were used for modelling fitting. Setting: University of California, Davis Medical Center (Sacramento, California, USA). Academic, single-centre, severe asthma subspecialty clinic. Participants: 612 screened, 223 eligible and 165 adult patients were included in the final study (N=165; 31 statin users and 134 non-users). Primary and secondary outcome measures: The primary endpoint was asthma control as measured by the Asthma Control Test (ACT). The secondary endpoints included lung function, symptoms and the need for corticosteroid burst and peripheral eosinophil count. Results: At baseline, statin users compared to nonusers were older, had lower lung function (FEV 1% predicted, FEV1, forced vital capacity and FEF 25-75%) and had a higher prevalence of comorbid conditions. Statin use was associated with more aspirin and ipratropium inhaler use than in non-users. Patients in both groups were obese (body mass index ≥ 30). Statin users had better asthma symptom control compared to non-users (higher adjusted mean ACT score by 2.2±0.94 points, p<0.02). Median statin use was for 1 year. There were no statistically significant differences in lung function, corticosteroid or rescue bronchodilator use or peripheral eosinophilia between the two groups. Conclusions: In our severe asthma referral population, statin users already taking inhaled controller therapy achieved better asthma control compared to non-users. The implications of this study is that patients with severe asthma could potentially benefit from added statin treatment. Because our study population was on average obese, the obese severe asthmatic may be a viable asthma subphenotype for further studies. Prospective randomised clinical trials evaluating the safety and efficacy of statins in severe asthma are warranted.

AB - Objectives: We hypothesised that severe asthmatics taking a statin drug, in addition to inhaled corticosteroids/long-acting β-agonist inhaler therapy, would have better asthma symptom control and improved lung function compared to their controls. Study design: A retrospective, cross-sectional study of 165 patients with severe asthma seen from 2001-2008. Hierarchical linear and logistic regression models were used for modelling fitting. Setting: University of California, Davis Medical Center (Sacramento, California, USA). Academic, single-centre, severe asthma subspecialty clinic. Participants: 612 screened, 223 eligible and 165 adult patients were included in the final study (N=165; 31 statin users and 134 non-users). Primary and secondary outcome measures: The primary endpoint was asthma control as measured by the Asthma Control Test (ACT). The secondary endpoints included lung function, symptoms and the need for corticosteroid burst and peripheral eosinophil count. Results: At baseline, statin users compared to nonusers were older, had lower lung function (FEV 1% predicted, FEV1, forced vital capacity and FEF 25-75%) and had a higher prevalence of comorbid conditions. Statin use was associated with more aspirin and ipratropium inhaler use than in non-users. Patients in both groups were obese (body mass index ≥ 30). Statin users had better asthma symptom control compared to non-users (higher adjusted mean ACT score by 2.2±0.94 points, p<0.02). Median statin use was for 1 year. There were no statistically significant differences in lung function, corticosteroid or rescue bronchodilator use or peripheral eosinophilia between the two groups. Conclusions: In our severe asthma referral population, statin users already taking inhaled controller therapy achieved better asthma control compared to non-users. The implications of this study is that patients with severe asthma could potentially benefit from added statin treatment. Because our study population was on average obese, the obese severe asthmatic may be a viable asthma subphenotype for further studies. Prospective randomised clinical trials evaluating the safety and efficacy of statins in severe asthma are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84885359620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885359620&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2013-003314

DO - 10.1136/bmjopen-2013-003314

M3 - Article

C2 - 23943778

AN - SCOPUS:84885359620

VL - 3

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 8

M1 - e003314

ER -